Economic Evaluation in Genomic Medicine

ISBN-13: 9780128014974 / Angielski / Miękka / 2015 / 174 str.

Vasilios Fragoulakis

Opis

Economic Evaluation in Genomic Medicine introduces health economics and economic evaluation to genomic clinicians and researchers, while also introducing the topic to health economists. Each chapter includes an executive summary, questions, and case studies, along with supplementary online materials, including process guides, maps, flow charts, diagrams, and economic evaluation spreadsheets to enhance the learning process. The text can easily be used as course material for related graduate and undergraduate courses, providing a succinct overview of the existing, state-of-the-art application of economic evaluation to genomic healthcare and precision medicine.

• Interrelates economic evaluation and genomic medicine
• Instructs healthcare professionals and bioscientists about economic evaluation in genomic medicine
• Teaches health economists about application of economic evaluation in genomic medicine
• Introduces health economics and economic evaluation to clinicians and researchers involved in genomics
• Includes process guides, maps, flow charts and diagrams

Recenzje

"...provides a useful introduction to health economics for non-specialists interested in how it can be applied to genomics, and the relevance of this on policy, reimbursement, and availability of diagnostics and related therapies." --European Journal of Human Genetics

Spis treści

1. Economic evaluation in healthcare: Evidence-based medicine and evidence-based health economics2. Genomic Medicine today: an introduction for health economists3. Economic evaluation and genomic medicine: What can they learn from each other?4. Introduction to the technical issues of economic evaluation5. Advanced methodological aspects in the economic evaluation 6. Economic evaluation in the genomic era: Some examples from the field7. Special requirements for economic evaluation and health technology assessment in genomic medicine 8. A new methodological approach for cost-effectiveness analysis in Genomic Medicine9. Conclusions and future perspectives

O autorze

Christina Mitropoulou is Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine. Her research interests revolve around the health economic evaluation of genome-guided therapeutic interventions. Also, Christina Mitropoulou participates as Executive Committee member of the Ubiquitous Pharmacogenomics (U-PGx) project and coordinates the health economic evaluation of the PREPARE clinical study on pre-emptive Pharmacogenomics testing, involving approx. 8000 patients from 7 clinical sites and she is an active member of the Pharmacogenomics Access and Reimbursement Coalition.
Christina Mitropoulou has published several original articles on this topic in leading scientific journals and has edited two textbooks on economic evaluation in Genomic Medicine that are published by Elsevier/Academic Press. Dr. Patrinos is internationally renowned for his involvement in the field of pharmacogenomics research. His research includes discovery work and addresses the issue of clinical implementation of pharmacogenomics in a holistic manner, including wet- and dry-lab, as well as public health genomics approaches. Dr. Patrinos has also a keen interest in the clinical implementation of genomic medicine in resource-limited environments.